Clinical Cancer Research最新文献

筛选
英文 中文
Metabolomic Prediction of Breast Cancer Treatment-Induced Neurologic and Metabolic Toxicities. 乳腺癌治疗引起的神经和代谢毒性的代谢组学预测。
IF 1 1区 医学
Clinical Cancer Research Pub Date : 2024-10-15 DOI: 10.1158/1078-0432.CCR-24-0195
Max Piffoux, Jérémie Jacquemin, Mélanie Pétéra, Stéphanie Durand, Angélique Abila, Delphine Centeno, Charlotte Joly, Bernard Lyan, Anne-Laure Martin, Sibille Everhard, Sandrine Boyault, Barbara Pistilli, Marion Fournier, Philippe Rouanet, Julie Havas, Baptiste Sauterey, Mario Campone, Carole Tarpin, Marie-Ange Mouret-Reynier, Olivier Rigal, Thierry Petit, Christine Lasset, Aurélie Bertaut, Paul Cottu, Fabrice André, Ines Vaz-Luis, Estelle Pujos-Guillot, Youenn Drouet, Olivier Trédan
{"title":"Metabolomic Prediction of Breast Cancer Treatment-Induced Neurologic and Metabolic Toxicities.","authors":"Max Piffoux, Jérémie Jacquemin, Mélanie Pétéra, Stéphanie Durand, Angélique Abila, Delphine Centeno, Charlotte Joly, Bernard Lyan, Anne-Laure Martin, Sibille Everhard, Sandrine Boyault, Barbara Pistilli, Marion Fournier, Philippe Rouanet, Julie Havas, Baptiste Sauterey, Mario Campone, Carole Tarpin, Marie-Ange Mouret-Reynier, Olivier Rigal, Thierry Petit, Christine Lasset, Aurélie Bertaut, Paul Cottu, Fabrice André, Ines Vaz-Luis, Estelle Pujos-Guillot, Youenn Drouet, Olivier Trédan","doi":"10.1158/1078-0432.CCR-24-0195","DOIUrl":"10.1158/1078-0432.CCR-24-0195","url":null,"abstract":"<p><strong>Purpose: </strong>Long-term treatment-related toxicities, such as neurologic and metabolic toxicities, are major issues in breast cancer. We investigated the interest of metabolomic profiling to predict toxicities.</p><p><strong>Experimental design: </strong>Untargeted high-resolution metabolomic profiles of 992 patients with estrogen receptor (ER)+/HER2- breast cancer from the prospective CANTO cohort were acquired (n = 1935 metabolites). A residual-based modeling strategy with discovery and validation cohorts was used to benchmark machine learning algorithms, taking into account confounding variables.</p><p><strong>Results: </strong>Adaptive Least Absolute Shrinkage and Selection (adaptive LASSO) has a good predictive performance, has limited optimism bias, and allows the selection of metabolites of interest for future translational research. The addition of low-frequency metabolites and nonannotated metabolites increases the predictive power. Metabolomics adds extra performance to clinical variables to predict various neurologic and metabolic toxicity profiles.</p><p><strong>Conclusions: </strong>Untargeted high-resolution metabolomics allows better toxicity prediction by considering environmental exposure, metabolites linked to microbiota, and low-frequency metabolites.</p>","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":" ","pages":"4654-4666"},"PeriodicalIF":10.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the FGFR Pathway in Patients with Advanced Solid Tumors. 针对晚期实体瘤患者的表皮生长因子受体通路。
IF 1 1区 医学
Clinical Cancer Research Pub Date : 2024-10-15 DOI: 10.1158/1078-0432.CCR-24-1711
Chadi Hage Chehade, Zeynep Irem Ozay, Neeraj Agarwal
{"title":"Targeting the FGFR Pathway in Patients with Advanced Solid Tumors.","authors":"Chadi Hage Chehade, Zeynep Irem Ozay, Neeraj Agarwal","doi":"10.1158/1078-0432.CCR-24-1711","DOIUrl":"10.1158/1078-0432.CCR-24-1711","url":null,"abstract":"<p><p>In the phase II FUZE trial targeting the FGFR pathway, Debio 1347 showed limited antitumor activity and manageable toxicity in patients with advanced solid tumors. Results from transcriptome-based analysis enhanced our understanding of the genomic landscape of FGFR fusion-driven tumors, informing clinical trial design and generating hypotheses for resistance mechanisms. See related article by Grivas et al., p. 4572.</p>","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":" ","pages":"4549-4551"},"PeriodicalIF":10.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome. 新诊断胶质母细胞瘤的远端神经炎症与不利的临床结果有关
IF 1 1区 医学
Clinical Cancer Research Pub Date : 2024-10-15 DOI: 10.1158/1078-0432.CCR-24-1563
Laura M Bartos, Stefanie Quach, Valerio Zenatti, Sabrina V Kirchleitner, Jens Blobner, Karin Wind-Mark, Zeynep Ilgin Kolabas, Selin Ulukaya, Adrien Holzgreve, Viktoria C Ruf, Lea H Kunze, Sebastian T Kunte, Leonie Hoermann, Marlies Härtel, Ha Eun Park, Mattes Groß, Nicolai Franzmeier, Artem Zatcepin, Adrian Zounek, Lena Kaiser, Markus J Riemenschneider, Robert Perneczky, Boris-Stephan Rauchmann, Sophia Stöcklein, Sibylle Ziegler, Jochen Herms, Ali Ertürk, Joerg C Tonn, Niklas Thon, Louisa von Baumgarten, Matthias Prestel, Sabina Tahirovic, Nathalie L Albert, Matthias Brendel
{"title":"Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome.","authors":"Laura M Bartos, Stefanie Quach, Valerio Zenatti, Sabrina V Kirchleitner, Jens Blobner, Karin Wind-Mark, Zeynep Ilgin Kolabas, Selin Ulukaya, Adrien Holzgreve, Viktoria C Ruf, Lea H Kunze, Sebastian T Kunte, Leonie Hoermann, Marlies Härtel, Ha Eun Park, Mattes Groß, Nicolai Franzmeier, Artem Zatcepin, Adrian Zounek, Lena Kaiser, Markus J Riemenschneider, Robert Perneczky, Boris-Stephan Rauchmann, Sophia Stöcklein, Sibylle Ziegler, Jochen Herms, Ali Ertürk, Joerg C Tonn, Niklas Thon, Louisa von Baumgarten, Matthias Prestel, Sabina Tahirovic, Nathalie L Albert, Matthias Brendel","doi":"10.1158/1078-0432.CCR-24-1563","DOIUrl":"10.1158/1078-0432.CCR-24-1563","url":null,"abstract":"<p><strong>Purpose: </strong>Current therapy strategies still provide only limited success in the treatment of glioblastoma, the most frequent primary brain tumor in adults. In addition to the characterization of the tumor microenvironment, global changes in the brain of patients with glioblastoma have been described. However, the impact and molecular signature of neuroinflammation distant of the primary tumor site have not yet been thoroughly elucidated.</p><p><strong>Experimental design: </strong>We performed translocator protein (TSPO)-PET in patients with newly diagnosed glioblastoma (n = 41), astrocytoma WHO grade 2 (n = 7), and healthy controls (n = 20) and compared TSPO-PET signals of the non-lesion (i.e., contralateral) hemisphere. Back-translation into syngeneic SB28 glioblastoma mice was used to characterize Pet alterations on a cellular level. Ultimately, multiplex gene expression analyses served to profile immune cells in remote brain.</p><p><strong>Results: </strong>Our study revealed elevated TSPO-PET signals in contralateral hemispheres of patients with newly diagnosed glioblastoma compared to healthy controls. Contralateral TSPO was associated with persisting epileptic seizures and shorter overall survival independent of the tumor phenotype. Back-translation into syngeneic glioblastoma mice pinpointed myeloid cells as the predominant source of contralateral TSPO-PET signal increases and identified a complex immune signature characterized by myeloid cell activation and immunosuppression in distant brain regions.</p><p><strong>Conclusions: </strong>Neuroinflammation within the contralateral hemisphere can be detected with TSPO-PET imaging and associates with poor outcome in patients with newly diagnosed glioblastoma. The molecular signature of remote neuroinflammation promotes the evaluation of immunomodulatory strategies in patients with detrimental whole brain inflammation as reflected by high TSPO expression.</p>","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":" ","pages":"4618-4634"},"PeriodicalIF":10.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11474166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141987561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-cell Lymphomas. FDA 批准摘要:Polatuzumab Vedotin 用于部分大 B 细胞淋巴瘤的一线治疗。
IF 11.5 1区 医学
Clinical Cancer Research Pub Date : 2024-10-15 DOI: 10.1158/1078-0432.ccr-24-1729
Maryam Sarraf Yazdy,Yvette L Kasamon,Wenjuan Gu,Lisa R Rodriguez,Susan Jin,Vishal Bhatnagar,Nicholas C Richardson,Marc R Theoret,Richard Pazdur,Nicole J Gormley
{"title":"FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-cell Lymphomas.","authors":"Maryam Sarraf Yazdy,Yvette L Kasamon,Wenjuan Gu,Lisa R Rodriguez,Susan Jin,Vishal Bhatnagar,Nicholas C Richardson,Marc R Theoret,Richard Pazdur,Nicole J Gormley","doi":"10.1158/1078-0432.ccr-24-1729","DOIUrl":"https://doi.org/10.1158/1078-0432.ccr-24-1729","url":null,"abstract":"In April 2023, the U.S. Food and Drug Administration granted regular approval to polatuzumab vedotin-piiq in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (pola+R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma, not otherwise specified or high-grade B-cell lymphoma and who have an International Prognostic Index score of 2 or greater. Approval was based on POLARIX, a randomized, double-blinded, placebo-controlled trial evaluating the superiority of substituting vincristine with polatuzumab vedotin in the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen as first-line therapy for patients with large B-cell lymphoma (LBCL). Efficacy was based on investigator-assessed progression-free survival (PFS) in 879 patients who were randomized to receive pola+R-CHP or R-CHOP, followed by two cycles of rituximab alone. PFS was statistically significantly longer with pola+R-CHP with a HR of 0.73 [95% CI: 0.57, 0.95] and log-rank p-value of 0.0177 (two-sided α=0.05). There was no improvement demonstrated in the key secondary endpoints of CR rate at the end of therapy or overall survival (OS). Several issues raised uncertainty about the benefit-risk of polatuzumab vedotin in this curative-intent setting including the modest PFS benefit of pola+R-CHP and lack of OS benefit. The application was therefore presented at an Oncology Drug Advisory Committee. This article summarizes key aspects of the regulatory review, including perspectives on PFS and OS results and other endpoints.","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":"8 1","pages":""},"PeriodicalIF":11.5,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction: Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells. 撤回:扩散型胃腺癌的化疗耐受性由癌干样细胞中的 RhoA 激活介导
IF 1 1区 医学
Clinical Cancer Research Pub Date : 2024-10-15 DOI: 10.1158/1078-0432.CCR-24-2133
Changhwan Yoon, Soo-Jeong Cho, Bülent Arman Aksoy, Do Joong Park, Nikolaus Schultz, Sandra W Ryeom, Sam S Yoon
{"title":"Retraction: Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells.","authors":"Changhwan Yoon, Soo-Jeong Cho, Bülent Arman Aksoy, Do Joong Park, Nikolaus Schultz, Sandra W Ryeom, Sam S Yoon","doi":"10.1158/1078-0432.CCR-24-2133","DOIUrl":"10.1158/1078-0432.CCR-24-2133","url":null,"abstract":"","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":"30 20","pages":"4802"},"PeriodicalIF":10.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice. 根据 BRCA1/2 和基于疤痕的 HRD 特征在现实世界中对卵巢癌进行 PARP 抑制剂维持治疗的有效性。
IF 1 1区 医学
Clinical Cancer Research Pub Date : 2024-10-15 DOI: 10.1158/1078-0432.CCR-24-1225
Debra L Richardson, Julia C F Quintanilha, Natalie Danziger, Gerald Li, Ethan Sokol, Alexa B Schrock, Ericka Ebot, Neeru Bhardwaj, Tanesha Norris, Anosheh Afghahi, Anthony Frachioni, Christina Washington, Lauren Dockery, Julia Elvin, Ryon P Graf, Kathleen N Moore
{"title":"Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice.","authors":"Debra L Richardson, Julia C F Quintanilha, Natalie Danziger, Gerald Li, Ethan Sokol, Alexa B Schrock, Ericka Ebot, Neeru Bhardwaj, Tanesha Norris, Anosheh Afghahi, Anthony Frachioni, Christina Washington, Lauren Dockery, Julia Elvin, Ryon P Graf, Kathleen N Moore","doi":"10.1158/1078-0432.CCR-24-1225","DOIUrl":"10.1158/1078-0432.CCR-24-1225","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of the study was to compare the effectiveness of PARP inhibitor maintenance therapy (mPARPi) in real-world practice by biomarker status [BRCA1/2 alterations (BRCAalt) and a homologous recombination deficiency signature (HRDsig)] in advanced ovarian cancer.</p><p><strong>Experimental design: </strong>Patients with ovarian cancer receiving first-line platinum-based chemotherapy and either mPARPi or no maintenance were included. Patient data were obtained by a US-based de-identified ovarian cancer Clinico-Genomic Database, from ∼280 US cancer clinics (01/2015-03/2023). Real-world progression-free survival (rwPFS) and overall survival (rwOS) were compared by biomarker status using Cox models, weighted by propensity scores.</p><p><strong>Results: </strong>Of 673 patients, 160 received mPARPi [31.2% BRCAalt and 51.9% HRDsig(+)] and 513 no maintenance [15.6% BRCAalt and 34.1% HRDsig(+)]. BRCAalt patients receiving mPARPi versus no maintenance had favorable rwPFS [HR, 0.48; 95% confidence interval (CI), 0.26-0.87; P = 0.0154], as did BRCA wild-type (WT; HR, 0.76; 95% CI, 0.57-1.01; P = 0.0595). Favorable rwOS was not observed with mPARPi for BRCAalt or BRCA-WT. HRDsig(+) patients receiving mPARPi versus no maintenance had favorable rwPFS (HR, 0.36; 95% CI, 0.24-0.55; P < 0.001) and numerically favorable rwOS (HR, 0.46; 95% CI, 0.21-1.02; P = 0.0561). No differences were observed for HRDsig(-). mPARPi treatment interaction was observed for HRDsig(+) versus HRDsig(-) (rwPFS P < 0.001/rwOS P = 0.016) but not for BRCAalt versus BRCA-WT. Patients with BRCA-WT/HRDsig(+) receiving mPARPi had favorable rwPFS (HR, 0.40; 95% CI, 0.22-0.72; P = 0.003), whereas no difference was observed for BRCA-WT/HRDsig(-).</p><p><strong>Conclusions: </strong>HRDsig predicted benefit of mPARPi better than BRCAalt. Patients with HRDsig(+) status experienced favorable outcomes, even if they had BRCA-WT status. In contrast, patients with HRDsig(-) status did not show significant benefit from mPARPi treatment. HRDsig might predict benefit from mPARPi regardless of BRCAalt status.</p>","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":" ","pages":"4644-4653"},"PeriodicalIF":10.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11474169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors. 颅外恶性横纹肌瘤的临床和分子风险因素--建立高风险肿瘤的综合模型。
IF 1 1区 医学
Clinical Cancer Research Pub Date : 2024-10-15 DOI: 10.1158/1078-0432.CCR-23-3489
Victoria E Fincke, Mona Steinbügl, Hye-Jung E Chun, Karolina Nemes, Marlena Mucha, Maurice Loßner, Felix Dorn, Katharina Gastberger, Sebastian Bühner, Martin Sill, Thomas Kröncke, Reiner Siebert, Patrick Melchior, Rhoikos Furtwängler, Matthias Schlesner, Christian Vokuhl, Christoph Röcken, Pascal D Johann, Michael C Frühwald
{"title":"Clinical and Molecular Risk Factors in Extracranial Malignant Rhabdoid Tumors: Toward an Integrated Model of High-Risk Tumors.","authors":"Victoria E Fincke, Mona Steinbügl, Hye-Jung E Chun, Karolina Nemes, Marlena Mucha, Maurice Loßner, Felix Dorn, Katharina Gastberger, Sebastian Bühner, Martin Sill, Thomas Kröncke, Reiner Siebert, Patrick Melchior, Rhoikos Furtwängler, Matthias Schlesner, Christian Vokuhl, Christoph Röcken, Pascal D Johann, Michael C Frühwald","doi":"10.1158/1078-0432.CCR-23-3489","DOIUrl":"10.1158/1078-0432.CCR-23-3489","url":null,"abstract":"<p><strong>Purpose: </strong>Extracranial malignant rhabdoid tumors (eMRT) are a challenging entity. Despite the use of multimodal treatment approaches, therapy failure occurs in 55% to 67% of these. Molecular markers for identification of patients at increased risk for relapse or refractory (R/R) disease are not available. Clinical characteristics may only insufficiently predict the individual course of disease.</p><p><strong>Experimental design: </strong>Using the EU-RHAB database, we analyzed a cohort of 121 patients with eMRT clinically. For 81 patients, molecular and clinical data were available, which were further complemented with publicly available DNA molecular data from 92 eMRTs. We aimed to delineate molecular risk factors by dissecting the DNA methylome of these tumors. Moreover, we establish clinical characteristics and treatment details of R/R disease in a subcohort of 80 patients.</p><p><strong>Results: </strong>Using consensus hierarchical clustering, we identified three distinct subgroups, one of which (eMRT standard risk) was associated with significantly improved survival, irrespective of germline status and/or localization. At the transcriptome level, this subgroup was characterized by an overexpression of genes involved in muscle development. A relevant proportion of patients developed distant relapses or progressions; the median time to the event was 4 months, underlining the need for early identification and risk stratification of R/R disease. The overall survival was significantly decreased in patients with progressive disease when compared with relapse cases, and reaching complete remission during salvage therapy provided a survival benefit.</p><p><strong>Conclusions: </strong>Our analysis of eMRT in this comprehensive cohort provides novel insights into the patterns of relapse and integrates molecular and clinical risk factors to guide clinical decision-making.</p>","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":" ","pages":"4667-4680"},"PeriodicalIF":10.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer. 外周血中的 KIR2DL2/DL3+NKs 和 Helios+Tregs 可预测转移性肾细胞癌患者对 nivolumab 的反应。
IF 1 1区 医学
Clinical Cancer Research Pub Date : 2024-10-15 DOI: 10.1158/1078-0432.CCR-24-0729
Sara Santagata, Anna Maria Trotta, Crescenzo D'Alterio, Maria Napolitano, Giuseppina Rea, Marilena Di Napoli, Luigi Portella, Caterina Ieranò, Giuseppe Guardascione, Elisabetta Coppola, Christophe Caux, Bertrand Dubois, Helen J Boyle, Joan Carles, Sabrina Rossetti, Rosa Azzaro, Florinda Feroce, Sisto Perdonà, Mario Fordellone, Anna Maria Bello, Daniela Califano, Paolo Chiodini, Sandro Pignata, Stefania Scala
{"title":"KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.","authors":"Sara Santagata, Anna Maria Trotta, Crescenzo D'Alterio, Maria Napolitano, Giuseppina Rea, Marilena Di Napoli, Luigi Portella, Caterina Ieranò, Giuseppe Guardascione, Elisabetta Coppola, Christophe Caux, Bertrand Dubois, Helen J Boyle, Joan Carles, Sabrina Rossetti, Rosa Azzaro, Florinda Feroce, Sisto Perdonà, Mario Fordellone, Anna Maria Bello, Daniela Califano, Paolo Chiodini, Sandro Pignata, Stefania Scala","doi":"10.1158/1078-0432.CCR-24-0729","DOIUrl":"10.1158/1078-0432.CCR-24-0729","url":null,"abstract":"<p><strong>Purpose: </strong>To identify predictive factors of nivolumab sensitivity, peripheral blood NKs and regulatory T-cell (Treg) were evaluated in patients with metastatic renal cell carcinoma (mRCC) enrolled in the REVOLUTION trial.</p><p><strong>Experimental design: </strong>Fifty-seven mRCCs being treated with nivolumab, as at least second-line of therapy, and 62 healthy donors were longitudinally evaluated (0-1-3-6-12 months) for peripheral NKs and Tregs, phenotype, and function. Multivariable logistic regression was conducted to identify the independent predictors. The 0.632+ internal cross-validation was used to avoid overfitting. The best cutoff value based on a 3-month clinical response was applied to progression-free survival (PFS) and overall survival (OS). Kaplan-Meier curves for PFS and OS were produced.</p><p><strong>Results: </strong>At pretreatment, mRCCs displayed high frequency of NKp46+NKs, NKp30+NKs, KIR2DL1+NKs, KIR2DL2/DL3+NKs, and PD1+NKs with reduced NK degranulation as well as high frequency of Tregs, PD1+Tregs, Helios+Tregs, and ENTPD1+Tregs. Responder patients, identified as a clinical response after 3 months of treatment, presented at pretreatment significantly low CD3+, high KIR2DL2/DL3+NKs, high PD1+Tregs, and high Helios+Tregs. Upon multivariate analysis, only KIR2DL2/DL3NKs and Helios+Tregs held as independent predictors of nivolumab responsiveness. The KIR2DL2/DL3+NKs >35.3% identified patients with longer OS, whereas the Helios+Tregs >34.3% displayed significantly longer PFS. After 1-month of nivolumab, responder patients showed low CD3+, high NKs, KIR2DL2/DL3+NKs, and ICOS+Tregs. Among these subpopulations, CD3+ and KIR2DL2/DL3+NKs held as independent predictors of nivolumab efficacy. Low CD3+ (≤71%) was significantly associated with longer PFS, whereas high KIR2DL2/DL3+NKs (>23.3%) were associated with both PFS and OS.</p><p><strong>Conclusions: </strong>Pretreatment evaluation of Helios+Tregs/KIR2DL2/DL3+NKs and 1-month posttreatment CD3+/ KIR2DL2/DL3+NKs will predict nivolumab response in mRCCs.</p>","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":" ","pages":"4755-4767"},"PeriodicalIF":10.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11474171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is It Time to Resist Using RECIST as a Primary Endpoint for Rare Tumor Trials? 现在是时候拒绝将 RECIST 作为罕见肿瘤试验的主要终点了吗?
IF 1 1区 医学
Clinical Cancer Research Pub Date : 2024-10-15 DOI: 10.1158/1078-0432.CCR-24-1628
Brian A Van Tine, Sasha Haarberg
{"title":"Is It Time to Resist Using RECIST as a Primary Endpoint for Rare Tumor Trials?","authors":"Brian A Van Tine, Sasha Haarberg","doi":"10.1158/1078-0432.CCR-24-1628","DOIUrl":"10.1158/1078-0432.CCR-24-1628","url":null,"abstract":"<p><p>Epithelioid hemangioendothelioma is an ultra-rare cancer driven by YAP-CAMTA1 fusion. Based on the link of the fusion to the MEK pathway, SARC33 was performed. It is a phase 2 trial examining trametinib that missed its primary objective by RECIST but demonstrated patient-reported outcome benefits in improved pain. See related article by Schuetze et al., p. 4584.</p>","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":" ","pages":"4552-4553"},"PeriodicalIF":10.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling Commonalities: Exploring Shared Characteristics in Clear-Cell Carcinomas of the Gynecologic Tract. 揭示共性:探索妇科透明细胞癌的共同特征。
IF 1 1区 医学
Clinical Cancer Research Pub Date : 2024-10-15 DOI: 10.1158/1078-0432.CCR-24-1205
Felix Blanc-Durand, Natalie Y L Ngoi, Diana G S Lim, David S P Tan
{"title":"Unveiling Commonalities: Exploring Shared Characteristics in Clear-Cell Carcinomas of the Gynecologic Tract.","authors":"Felix Blanc-Durand, Natalie Y L Ngoi, Diana G S Lim, David S P Tan","doi":"10.1158/1078-0432.CCR-24-1205","DOIUrl":"10.1158/1078-0432.CCR-24-1205","url":null,"abstract":"<p><p>Clear-cell carcinomas (CCC) arising from the gynecologic tract (including from the ovary, endometrium, cervix, vulva, or vagina) represent rare but clinically significant entities with intriguing overlapping characteristics. Epidemiologically, CCCs exhibit a predilection for women of Asian ethnicity and are often associated with a previous or synchronous diagnosis of endometriosis. Pathologically, despite originating from different primary organs, CCCs of the gynecologic tract show similar morphologic and immunophenotypic features on traditional histopathology, such as the expression of napsin A and hepatocyte nuclear factor 1β on IHC, without the expression of Wilms tumor 1. Well-described molecular characteristics of these cancers include recurrent mutations in genes such as ARID1A, PIK3CA, and/or PTEN, although significant variations exist across the different anatomic sites. Therapeutically, optimal management remains challenging due to the relative rarity of CCCs and limited subtype-specific clinical trials. Surgery remains the cornerstone of treatment, often complemented by systemic chemotherapy. However, promising drugs targeting angiogenesis or the immune microenvironment have emerged in recent years, leading to clinical successes, and are likely to reshape the therapeutic landscape of gynecologic CCC. This review summarizes the commonalities and disparities in terms of epidemiology, pathology, molecular features, and therapeutic approach, among CCCs of different anatomic origin, offering a foundation for further research and dedicated therapeutic interventions for these malignancies.</p>","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":" ","pages":"4557-4565"},"PeriodicalIF":10.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141981853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信